![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/fintepla-fenfluramine-results-examining-its-impact-in-managing-generalized-tonic-clonic-seizures-in-developmental-and-epileptic-encephalopathies-published-in-epilepsia-302179742.html
https://www.prnewswire.com/news-releases/ucb-announces-publication-in-the-lancet-of-phase-3-bimzelx-bimekizumab-bkzx-trials-in-moderate-to-severe-hidradenitis-suppurativa-302153768.html
https://www.prnewswire.com/news-releases/bimzelx-48-week-phase-3-analyses-in-moderate-to-severe-hidradenitis-suppurativa-showed-sustained-improvements-in-skin-pain-and-draining-tunnel-count-302083639.html
https://www.fiercepharma.com/pharma/seeking-blockbuster-status-ucb-eyes-four-new-indications-psoriasis-med-bimzelx-2024
https://www.prnewswire.com/news-releases/ucb-on-growth-path-for-a-decade-plus-302073984.html
https://www.prnewswire.com/news-releases/ucb-presents-late-breaking-posters-at-child-neurology-society-meeting-301947405.html
https://www.fiercepharma.com/pharma/ucbs-bimekizumab-remains-fda-limbo-agency-closes-inspection
https://www.fiercepharma.com/pharma/lundbeck-replaces-retiring-ceo-dunsire-ucb-exec-after-breaking-sales-record
https://www.pharmaceutical-technology.com/news/ariceum-ucb-therapies-cancer/